Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320928 | 0.88 | SOS1 (0.38) | MEN1KMT2ASCN9ATSHRNPC1 | |
| SCHEMBL14921743 | 0.86 | SMN1; SMN2 (0.39) | MEN1KMT2ATSHRNPC1RAB9A | |
| SCHEMBL322245 | 0.85 | SLC22A12 (0.41) | MEN1KMT2ASCN9ATSHRNPC1 | |
| SCHEMBL17048560 | 0.85 | BMP1 (0.37) | MEN1KMT2ASCN9ATSHRNPC1 | |
| SCHEMBL29668838 | 0.84 | KEAP1 (0.41) | MEN1KMT2ASCN9ANPC1RAB9A | |
| SCHEMBL17048628 | 0.84 | KEAP1 (0.41) | MEN1KMT2ASCN9ANPC1RAB9A | |
| SCHEMBL1095453 | 0.83 | SMN1; SMN2 (0.37) | MEN1KMT2ASCN9ATSHRNPC1 | |
| SCHEMBL319860 | 0.83 | NPC1 (0.39) | MEN1KMT2ASCN9ATSHRNPC1 | |
| SCHEMBL18882667 | 0.83 | SCN9A (0.37) | MEN1KMT2ASCN9ATSHRNPC1 | |
| SCHEMBL17048645 | 0.82 | SCN9A (0.49) | MEN1KMT2ASCN9ASMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2015130957-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals, Ltd. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130957-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals, Ltd. (US) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, SCN1A, CACNA1S | MEN1 374/4885KMT2A 3063/4885SCN9A 29/4885 |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPM6, SCN1A | MEN1 427/4885KMT2A 3328/4885SCN9A 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.